<DOC>
	<DOC>NCT02088918</DOC>
	<brief_summary>A Randomized, Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared with a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet under Fasting Conditions in Healthy Male Subjects</brief_summary>
	<brief_title>A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Nateglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age between 20 and 40 Signed informed consent Has a history of hypersensitivity to IP ingredients Hypertension or hyportension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>